Ardent Health Partners, Inc. (ARDT)vsAstraZeneca PLC (AZN)
ARDT
Ardent Health Partners, Inc.
$10.72
+0.28%
HEALTHCARE · Cap: $1.57B
AZN
AstraZeneca PLC
$161.85
+0.64%
HEALTHCARE · Cap: $252.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 858% more annual revenue ($61.37B vs $6.41B). AZN leads profitability with a 17.0% profit margin vs 1.2%. ARDT trades at a lower P/E of 19.6x. AZN earns a higher WallStSmart Score of 60/100 (C+).
ARDT
Hold40
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARDT.
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$161.85
$34.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 7.7% — below average capital efficiency
1.2% margin — thin
Operating margin of 3.4%
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDT
The strongest argument for ARDT centers on Price/Book.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 1.68 is elevated, increasing financial risk. Thin 1.2% margins leave little buffer for downturns.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ARDT profiles as a value stock while AZN is a mature play — different risk/reward profiles.
ARDT carries more volatility with a beta of 0.70 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 40/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc. is a leading healthcare organization based in Nashville, Tennessee, focused on providing high-quality, patient-driven care through an extensive network of hospitals and outpatient facilities. The company emphasizes innovation and operational excellence, offering a comprehensive range of acute care services tailored to the specific needs of the communities it serves. With a solid financial foundation and a strategic growth plan, Ardent is well-prepared to enhance healthcare access and improve patient outcomes in a dynamic healthcare environment.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?